{
    "clinical_study": {
        "@rank": "26730", 
        "arm_group": {
            "arm_group_label": "ATR-101", 
            "arm_group_type": "Experimental", 
            "description": "ATR-101 will be administered as capsules by mouth once per day to ascending dose cohorts"
        }, 
        "brief_summary": {
            "textblock": "This first-in-human study is designed to establish the safety and tolerability of ATR-101 in\n      patients with advanced adrenocortical carcinoma whose tumor has progressed on standard\n      therapy.  Information will also be collected to determine how long ATR-101 stays in the\n      blood, and if any effect on tumor progression is seen.  Biomarkers (blood and urine tests)\n      will determine if any effects on production of steroid hormones (cortisol, aldosterone,\n      estrogen and testosterone) are seen."
        }, 
        "brief_title": "Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma", 
        "condition": "Adrenocortical Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Adrenocortical Carcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        18 years;\n\n          -  Clinical confirmation of adrenocortical carcinoma that is locally advanced or\n             metastatic and not amendable to surgical resection;\n\n          -  Failed or declined mitotane (adjuvant or therapeutic) therapy or a platinum-based\n             chemotherapy regimen;\n\n          -  Able to understand and comply with the protocol requirements;\n\n          -  Willing and able to provide informed consent.\n\n        Exclusion Criteria:\n\n          -  Mitotane level > 5\n\n          -  Use of contraindicated concomitant medications\n\n          -  Unstable medical condition that, in the judgment of the investigator, could interfere\n             with study procedures or data interpretation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898715", 
            "org_study_id": "ATR-101-001"
        }, 
        "intervention": {
            "arm_group_label": "ATR-101", 
            "intervention_name": "ATR-101", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Adrenocortical carcinoma", 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48103"
                    }, 
                    "name": "University of Michigan Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MDAnderson Cancer Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma", 
        "overall_contact": {
            "last_name": "Marian Ijzerman, PhD", 
            "phone": "734-845-9300"
        }, 
        "overall_contact_backup": {
            "last_name": "Martin D Phillips, MD", 
            "phone": "734-845-9000"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse events will be recorded and tabulated by grade and system organ class according to CTCAE v 4.03.  Laboratory measures and ECGs will be assessed.", 
            "measure": "Frequency of dose-limiting toxicity and determination of maximum tolerated dose", 
            "safety_issue": "Yes", 
            "time_frame": "Occurrence of DLT at 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898715"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Plasma levels of ATR-101 will be assessed after daily oral dosing and pharmacokinetic parameters will be calculated.", 
                "measure": "Area under the plasma concentration versus time curve (AUC) of ATR-101", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 22"
            }, 
            {
                "measure": "Change in plasma cortisol levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline and day 22"
            }, 
            {
                "description": "CT or MRI scans will be read according to RECIST 1.1", 
                "measure": "Change in objective measurement of tumor size", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 8 weeks"
            }
        ], 
        "source": "Atterocor, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Atterocor, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}